AbbVie's Humira nabs orphan status in skin disease; GSK-backed poll boosts case for meningitis vaccines;

> AbbVie's ($ABBV) top-selling anti-inflammatory therapy Humira won an FDA orphan designation in the rare skin disease hidradenitis, making the drug eligible for 7 years of exclusivity in that indication. Report

> A new U.S. poll found that 83% of parents want their teens and young adults to be vaccinated against meningococcal disease; the survey was sponsored by GlaxoSmithKline ($GSK), which markets the men B shot Menhibrix. Release

> A generics maker is suing the FDA after the agency declared that its version of the Johnson & Johnson ($JNJ) ADHD med Concerta wasn't bioequivalent to the brand, nixing the copycat med's automatic substitution at pharmacies. Report

> The first set of American Urological Association guidelines for Peyronie's disease, in which scar tissue builds up in the penis, recommends Endo's ($ENDP) Xiaflex as a treatment option. Release

> Makovsky's health practice director Gil Bashe jumped ship to join rival PR firm Finn Partners, where he'll focus on growing the firm's business in biopharma. Report

> The health-focused communications agency KYNE recruited Novartis ($NVS) vet Maureen Byrne to head up its New York office. Report

And Finally... Merck KGaA could have trouble hitting healthcare heights. Report (sub. req.)

Suggested Articles

After showing Nucala could cut the rates of flares for hypereosinophilic syndrome, GSK is planning regulatory filings in 2020.

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Both IL-17A inhibitors have rolled out data showing they work in non-radiographic axial spondyloarthritis.